
簡要描述:Cisatracurium besylate 96946-42-8Cisatracurium Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration.
產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 96946-42-8 |
|---|---|---|---|
| 分子式 | C53H72N2O12.2C6H5O3S | 純度 | >98% |
| 分子量 | 1243.48 | 貨號 | abs47027707 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a nondepolarizing skeletal muscle rel | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Cisatracurium besylate 96946-42-8
| 產(chǎn)品描述 | |
| 描述 | Cisatracurium Besylate is a nondepolarizing skeletal muscle relaxant for intravenous administration. Cisatracurium Besylate acts on cholinergic receptors, blocking neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. The neuromuscular block produced by cisatracurium besylate is readily antagonized by anticholinesterase agents once recovery has started. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at the time of reversal, the longer the time required for recovery of neuromuscular function. Compared to other neuromuscular blocking agents, it is intermediate in its onset and duration of action. |
| 純度 | >98% |
| 儲存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 順ben磺阿曲庫銨;51W89 |
| 外觀 | 白色至淡黃色粉末 |
| 可溶性/溶解性 | DMSO : 229 mg/mL (184.2 mM) Ethanol : 229 mg/mL (184.2 mM) Water : 43 mg/mL (34.6 mM) |
| 生物活性 | |
| 靶點(diǎn) | AChR, Adrenergic Receptor |
| In vitro(體外研究) | Cisatracurium Besylate (51W89) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium Besylate (51W89) is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Neuroscience CancerCancer Metabolism Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
